title: Antisense oligonucleotides to human SQA-neuropeptide FF decrease morphine tolerance and dependence in mice.
abstract: Neuropeptide FF (Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-NH2) is able to modulate opioid analgesia. Intracerebroventricular treatment for 5 days with antisense-oligodeoxynucleotides complementary to the sequence of human SQA-neuropeptide FF (Ser-Gln-Ala-Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-NH2) precursor gene or by mismatch-oligodeoxynucleotides did not change the antinociceptive activity of morphine in the mouse tail flick test. In contrast, antisense- but not mismatch-oligodeoxynucleotides attenuated significantly the tolerance to the analgesic activity of morphine and the withdrawal syndrome precipitated by naloxone in morphine-treated mice. These treatments with oligodeoxynucleotides did not modify neuropeptide FF-immunoreactivity content in whole brain but repeated injections of an agonist of neuropeptide FF receptors increased the intensity of morphine tolerance. These results demonstrate the important role of neuropeptide FF in opioid pharmacodependence.
authors.affiliation: Institut de Pharmacologie et de Biologie Structurale, CNRS, Toulouse, France.
authors.forename: A
authors.initials: A
authors.lastname: Gelot
authors.forename: B
authors.initials: B
authors.lastname: Francés
authors.forename: S
authors.initials: S
authors.lastname: Gicquel
authors.forename: J M
authors.initials: JM
authors.lastname: Zajac
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D004361:Drug Tolerance; D006801:Humans; D007276:Injections, Intraventricular; D008297:Male; D051379:Mice; D009020:Morphine / Q000494:pharmacology*; D009021:Morphine Dependence / Q000188:drug therapy / Q000517:prevention & control*; D009292:Narcotic Antagonists / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D009294:Narcotics / Q000494:pharmacology; D020319:Oligodeoxyribonucleotides, Antisense / Q000494:pharmacology* / Q000627:therapeutic use; D009842:Oligopeptides / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D013375:Substance Withdrawal Syndrome / Q000517:prevention & control
chemical_list: D009292:Narcotic Antagonists; D009294:Narcotics; D020319:Oligodeoxyribonucleotides, Antisense; D009842:Oligopeptides; D009020:Morphine; C053651:phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide